Early-onset heart failure significantly elevates the risk of all-cause mortality

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at investigating the correlations between heart failure onset age and all-cause mortality.

FDA reviewers on Ipsen’s potential ultra-rare disease drug: Post-hoc analysis may be enough

Post-hoc analyses are generally a major no-no for the FDA, but agency reviewers signaled their openness to considering them in the case of Ipsen’s potential

June 27, 2023

Neoadjuvant PD-1 Blockade Boosts pCR Rates in Early Esophageal Cancer

SAN FRANCISCO — Adding an investigational PD-1 inhibitor to chemotherapy in the neoadjuvant setting significantly improved pathological complete response (pCR) rates for patients with resectable

January 23, 2024

An innovative eye stem cell transplant could help restore vision in people with chemical injuries

The first time Phillip Durst saw the big A on the chart, he could hardly believe it. It was the first in a series of

August 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.